|
|
News for Healthier Living
Hidden Proteotoxic Cargo May Undermine Stem Cell Therapy Success
Stem cell and cell-free extracellular vesicle (EV) therapies are entering clinical practice faster than their quality-control systems can adapt. This review argues that proteostatic fitness--the ability of donor cells to maintain protein homeostasis under stress--is an overlooked determinant of therapeutic success. Senescence during ex vivo expansion can impair protein quality control and enrich EV cargo with proteotoxic species, including oxidized superoxide dismutase 1 (SOD1). The authors propose that senescence burden and EV proteomic integrity should become critical quality attributes, with targeted clearance of misfolded SOD1 as a possible pre-transplant strategy. Such measures could better align manufacturing release tests with the oxidative and inflammatory stress that cells face after transplantation.
October 21, 2026
October 29 2026October 28 2026October 27 2026October 26 2026October 25 2026October 24 2026October 23 2026October 22 2026October 21 2026October 20 2026October 19 2026October 18 2026October 17 2026October 16 2026
|
|
|
|
|